Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Altimmune, Inc. ( ALT ) Q2 2026 Earnings Call August 12, 2026 8:30 AM EDT

Company Participants

Luis Sanay

Jerome Durso - Chairman, CEO & President

Christophe Arbet-Engels - Chief Medical Officer

Linda Richardson - Chief Commercial Officer

Gregory Weaver - Chief Financial Officer

Conference Call Participants

Thomas Smith - Leerink Partners LLC, Research Division

Michael DiFiore - Evercore ISI Institutional Equities, Research Division

Eliana Merle - Barclays Bank PLC, Research Division

Srikripa Devarakonda - Truist Securities, Inc., Research Division

Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division

Catherine Okoukoni - Citizens JMP Securities, LLC, Research Division

Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division

William Wood - B. Riley Securities, Inc., Research Division

Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division

Good morning, ladies and gentlemen. Welcome to the Altimmune Second Quarter 2026 Financial Results Conference Call.

As a reminder, this call is being recorded. I'm going to introduce your host for today's conference call, Luis Sanay, Vice President of Investor Relations. Luis, you may begin.

Thank you, operator, and good morning, everyone. Thank you for joining us for Altimmune's second quarter 2026 financial results and business update call. On today's call, you will hear from Jerry Durso, our Chairman and Chief Executive Officer; Dr. Christophe Arbet-Engels, Chief Medical Officer; Linda Richardson, Chief Commercial Officer; and Greg Weaver, Chief Financial Officer. Following management's prepared remarks, we'll open the line for questions. Our second quarter 2026 earnings release was issued this morning and can be found in the Investor Relations section of our website.

Before we begin, I would like to remind everyone that remarks made about future expectations, plans, and prospects constitute forward-looking statements for the purpose of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties